62019TJ0664_INF
Judgment of the General Court (Third Chamber) of 18 November 2020 –Allergan Holdings France v EUIPO – Dermavita (JUVEDERM ULTRA)
(Case T‑664/19)
(EU trade mark – Revocation proceedings – EU word mark JUVEDERM ULTRA – Genuine use of the mark – Use in connection with the goods in respect of which the mark was registered – Article 51(1)(a) of Regulation (EC) No 207/2009 (now Article 58(1)(a) of Regulation (EU) 2017/1001))
1.
EU trade mark – Surrender, revocation and invalidity – Causes of revocation – Absence of genuine use of a trade mark – Proof of use – Burden of proof
(Council Regulation No 207/2009, Art. 51)
(see para. 18)
2.
EU trade mark – Surrender, revocation and invalidity – Causes of revocation – Absence of genuine use of a trade mark – Word mark JUVEDERM ULTRA
(Council Regulation No 207/2009, Art. 15(1)(a))
(see paras 19, 20)
Re:
Action brought against the decision of the Fourth Board of Appeal of EUIPO of 18 July 2019 (Joined Cases R 1655/2018-4 and R 1723/2018-4), relating to revocation proceedings between Dermavita Co. and Allergan Holdings France.
Operative part
The Court:
1.
Dismisses the action;
2.
Orders Allergan Holdings France to pay the costs.